In the article "Precision medicine offers a glimmer of hope for Alzheimer's disease" by Melissa Healy, it is stated that has been Twenty years of searching for effective methods to find a cure or prevent Alzheimer's have been unsuccessful. According to Healy, there were 5.7 million Americans severely affected with no means of survival from this disease. The focus of this research is on a new experimental precision medicine study that has led to likely real-world results and the hope of a treatment for Alzheimer's. Say no to plagiarism. Get a tailor-made essay on "Why Violent Video Games Shouldn't Be Banned"? Get an original essay The author mainly discusses the approach to research studies of the dementia specialist gathered at the international conference of the Alzheimer's Assn. in Chicago to evaluate the real hope in both precision medicine and innovative clinical trial studies to be able to deliver new treatments for brain disease. The independent variable was the existing different stages of Alzheimer's in the patients. The dependent variable was the level of plaque reduction in the brains of patients with early Alzheimer's compared to a genetic substance typical of Alzheimer's, and 856 patients were enrolled in these innovative clinical trials for the BAN2401 case study. Regarding the case study, Anavex 2-73 was the patient's level of ability to reason, remember and independently carry out daily activities. By examining 32 patients with mild to moderate Alzheimer's and testing genetic compatibility with the substance for it to work successfully, according to the researchers. The researcher's results demonstrated the effectiveness of both precision drugs in Alzheimer's patients. From the results of the BAN2401 case study, patients who ingested a higher dosage of the drug for 18 months saw results in reduction of amyloid plaque in the brain; Unlike patients who took a higher dosage of the generic drug for the same number of months, outcomes declined slowly in 26 percent of patients. Regarding the Anavex case study, 2-73 patients who were genetically compatible with the drug and who took it for 57 weeks experienced surprising results, for example the patient communicated correctly, understood and carried out his daily routine. The researchers, in both studies, demonstrated successful results with their patients in clinical trials. The clinical study for BAN2401 has shown progress. According to James A. Hendrix, director of global science initiatives at the Alzheimer's Assn. He says that “clinical trials in Alzheimer's disease need to evolve,” trying new things and learning about other diseases such as cancer, moving closer to an effective way of therapy to treat this disease. He also says he would like to make progress in diagnosing the earliest symptoms before the disease takes effect and for people without symptoms. I agree with Hendrix's statement because his approach in expanding his research to explore other diseases such as cancer cure and desire to advance his research to find an early approach to detect this destructive brain disease It's a great idea. This will certainly have a global impact on our future and give hope to those genetically affected by this disease. As with other precision medicines, Anavex 2-73 has also shown progress. The author states that the researchers have extended their Alzheimer's clinical studies to Australia and North America, carrying out.